Merck reported Q3 FY 2016 earnings of $1.07 per share (versus $0.96 in Q3 FY 2015), beating analysts’ consensus estimate of $0.99.
The company’s quarterly revenues amounted to $10.536 bln (+4.6% y/y), beating analysts’ consensus estimate of $10.180 bln.
The company also issued guidance for FY 2016, raising EPS to $3.71-3.78 from $3.67-3.77 (versus analysts’ consensus estimate of $3.75) and revenue to $39.7-40.2 bln from $39.1-40.1 bln (versus analysts’ consensus estimate of $39.69 bln).
MRK rose to $$61.50 (+1.23%) in pre-market trading.
The post Company News: Merck (MRK) Q3 results beat analysts’ forecasts appeared first on forex-analytics.press.